Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
Md Yusof MY., Smith EMD., Ainsworth S., Armon K., Beresford MW., Brown M., Cherry L., Edwards CJ., Flora K., Gilman R., Griffiths B., Gordon C., Howard P., Isenberg D., Jordan N., Kaul A., Lanyon P., Laws PM., Lightsone L., Lythgoe H., Mallen CD., Marks SD., Maxwell N., Moraitis E., Nash C., Pepper RJ., Pilkington C., Psarras A., Rostron H., Skeates J., Skeoch S., Tremarias D., Wincup C., Zoma A., Vital EM.
The objective of this guideline is to provide up-to-date, evidence-based recommendations for the management of SLE that builds upon the existing treatment guideline for adults living with SLE published in 2017. This will incorporate advances in the assessment, diagnosis, monitoring, non-pharmacological and pharmacological management of SLE. General approaches to management as well as organ-specific treatment, including lupus nephritis and cutaneous lupus, will be covered. This will be the first guideline in SLE using a whole life course approach from childhood through adolescence and adulthood. The guideline will be developed with people with SLE as an important target audience in addition to healthcare professionals. It will include guidance related to emerging approved therapies and account for National Institute for Health and Care Excellence Technology Appraisals, National Health Service England clinical commissioning policies and national guidance relevant to SLE. The guideline will be developed using the methods and rigorous processes outlined in 'Creating Clinical Guidelines: Our Protocol' by the British Society for Rheumatology.